α—硫辛酸对2型糖尿病肾病患者血清内脂素的影响研究(1)
摘 要：目的 探讨α-硫辛酸对2型糖尿病患者血清内脂素的影响。方法 选取2型糖尿病合并肾病患者90例，按照尿微量白蛋白/肌酐(尿ACR)分为微量蛋白尿硫辛酸治疗组(尿ACR 30～300 μg/mg)30例，微量蛋白尿常规治疗组30例，大量蛋白尿硫辛酸治疗组(尿ACR>300 μg/mg)30例。常规治疗组给予降糖、降压治疗，硫辛酸治疗组分别在常规治疗基础上给予α-硫辛酸300 mg/d静脉滴注。疗程10 d。治疗前及疗程结束后测定所有参与者尿ACR及血清内脂素。结果 微量-常规组治疗后内脂素无改变(35.17±10.64 vs 33.28±9.51 pg/ml，P>0.05)，尿ACR无改变(59.5±29.4 vs 60.14±32.51μg/mg，P>0.05)；微量-硫辛酸组治疗后内脂素下降(33.31±9.5 vs 28.76±10.79 pg/ml，P<0.01)，尿ACR无改变(62.09±35.1 vs 58.29±30.08 μg/mg，P>0.05)；大量-硫辛酸组治疗后内脂素下降(65.7±17.0 vs 54.62±12.51 pg/ml，P<0.01)，尿ACR无改变(459.1±103.5 vs 443.61±109.44 μg/mg，P>0.05)。结论 α-硫辛酸治疗可以减低糖尿病肾病患者血清内脂素水平，但短疗程(10 d)硫辛酸治疗不能减少尿蛋白排泄率。
, 百拇医药
关键词：糖尿病肾病；α-硫辛酸；内脂素；尿蛋白排泄率
中图分类号：R587.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.14.019
文章编号：1006-1959(2018)14-0060-04
Abstract：Objective To investigate the effect of α-lipoic acid on serum visfatin in patients with type 2 diabetes mellitus.Methods 90 patients with type 2 diabetes mellitus complicated with nephropathy were enrolled，according to urinary microalbumin/creatinine (urine ACR)，30 cases of microalbuminuria treatment group(urine ACR 30～300μg/mg)，30 cases of microalbuminurial treatment group， and a large number of proteinuria lipoic acid treatment group( Urinary ACR>300 μg/mg)in 30 cases.The conventional treatment group was given hypoglycemic and antihypertensive treatment，and the lipoic acid treatment group was given an intravenous infusion of α-lipoic acid 300 mg/d on the basis of conventional treatment.The course of treatment is 10 d.All participants were tested for urinary ACR and serum visfatin before and after treatment.Results There was no change in visfatin after treatment in the micro-routine group(35.17±10.64vs33.28±9.51pg/ml，P>0.05)，and there was no change in urinary ACR(59.5±29.4vs60.14±32.51μg/mg，P>0.05)；The visfatin decreased after treatment with the micro-lipoic acid group(33.31±9.5vs28.76±10.79pg/ml，P<0.01)，and there was no change in urinary ACR(62.09±35.1vs 58.29±30.08 μg/mg，P>0.05)；The visfatin decreased after treatment in the high-lipoic acid group(65.7±17.0 vs54.62±12.51pg/ml，P<0.01)，and there was no change in urinary ACR(459.1±103.5vs443.61±109.44 μg/mg，P>0.05).Conclusion α-lipoic acid treatment can reduce serum visfatin levels in patients with diabetic nephropathy，but short-course(10 d)lipoic acid treatment can not reduce urinary protein excretion rate.
Key words：Diabetic nephropathy；α-lipoic acid；Visfatin；Urinary protein excretion rate
糖尿病腎病(diabetic nephropathy，DN)是常见的糖尿病微血管并发症之一，也是引起终末期肾病最常见的原因。DN的发病机制复杂，包括肾小球血流动力学异常，糖基化代谢产物堆积，蛋白激酶C激活等，慢性炎症反应和氧化应激也在其中起重要作用。脂肪因子内脂素可以诱导激活多种炎症因子，参与DN的发生与发展。本研究通过对糖尿病患者使用抗氧化剂硫辛酸，观察其内脂素及尿ACR的变化，以了解抗氧化剂对内脂素的影响。, 百拇医药(陆新虹 温玉洁 胡欣 马小燕)
, 百拇医药
关键词：糖尿病肾病；α-硫辛酸；内脂素；尿蛋白排泄率
中图分类号：R587.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.14.019
文章编号：1006-1959(2018)14-0060-04
Abstract：Objective To investigate the effect of α-lipoic acid on serum visfatin in patients with type 2 diabetes mellitus.Methods 90 patients with type 2 diabetes mellitus complicated with nephropathy were enrolled，according to urinary microalbumin/creatinine (urine ACR)，30 cases of microalbuminuria treatment group(urine ACR 30～300μg/mg)，30 cases of microalbuminurial treatment group， and a large number of proteinuria lipoic acid treatment group( Urinary ACR>300 μg/mg)in 30 cases.The conventional treatment group was given hypoglycemic and antihypertensive treatment，and the lipoic acid treatment group was given an intravenous infusion of α-lipoic acid 300 mg/d on the basis of conventional treatment.The course of treatment is 10 d.All participants were tested for urinary ACR and serum visfatin before and after treatment.Results There was no change in visfatin after treatment in the micro-routine group(35.17±10.64vs33.28±9.51pg/ml，P>0.05)，and there was no change in urinary ACR(59.5±29.4vs60.14±32.51μg/mg，P>0.05)；The visfatin decreased after treatment with the micro-lipoic acid group(33.31±9.5vs28.76±10.79pg/ml，P<0.01)，and there was no change in urinary ACR(62.09±35.1vs 58.29±30.08 μg/mg，P>0.05)；The visfatin decreased after treatment in the high-lipoic acid group(65.7±17.0 vs54.62±12.51pg/ml，P<0.01)，and there was no change in urinary ACR(459.1±103.5vs443.61±109.44 μg/mg，P>0.05).Conclusion α-lipoic acid treatment can reduce serum visfatin levels in patients with diabetic nephropathy，but short-course(10 d)lipoic acid treatment can not reduce urinary protein excretion rate.
Key words：Diabetic nephropathy；α-lipoic acid；Visfatin；Urinary protein excretion rate
糖尿病腎病(diabetic nephropathy，DN)是常见的糖尿病微血管并发症之一，也是引起终末期肾病最常见的原因。DN的发病机制复杂，包括肾小球血流动力学异常，糖基化代谢产物堆积，蛋白激酶C激活等，慢性炎症反应和氧化应激也在其中起重要作用。脂肪因子内脂素可以诱导激活多种炎症因子，参与DN的发生与发展。本研究通过对糖尿病患者使用抗氧化剂硫辛酸，观察其内脂素及尿ACR的变化，以了解抗氧化剂对内脂素的影响。, 百拇医药(陆新虹 温玉洁 胡欣 马小燕)